trending Market Intelligence /marketintelligence/en/news-insights/trending/yxZiCiBuhy5RvMHh6oc8mA2 content esgSubNav
In This List

Exelixis plans US drug application on positive cancer treatment results

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Exelixis plans US drug application on positive cancer treatment results

Exelixis Inc. said Oct. 10 its cabozantinib drug performed better against sunitinib in treating advanced kidney cancer, prompting the company to plan an application for the treatment in the U.S.

Results from randomized phase two trial with patients suffering from previously untreated advanced renal cell carcinoma showed cabozantinib decreasing rate of disease progression or death by 31% when compared to sunitinib, which is marketed by Pfizer Inc

Exelixis and partner Ipsen will jointly host a live webcast at 1 p.m. ET on Oct. 10 to discuss the study and its data.